Quick Answer
Rein Therapeutics, Inc. reported Net Income Loss of -$49.87 million for the year ending 2025.
- Rein Therapeutics, Inc. showed an increase of +20.7% in Net Income Loss from 2024 to 2025.
- This data is from Rein Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), Rein Therapeutics, Inc.'s Net Income Loss has declined by 287.3%.
- Historical annual values: Fiscal year 2025: -$49.87 million | Fiscal year 2024: -$62.88 million | Fiscal year 2023: -$15.73 million | Fiscal year 2022: -$27.33 million | Fiscal year 2021: -$26.16 million | Fiscal year 2020: -$27.33 million | Fiscal year 2019: -$29.37 million | Fiscal year 2018: -$31.55 million | Fiscal year 2017: -$22.60 million | Fiscal year 2016: -$18.12 million | Fiscal year 2015: -$12.88 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: